Clinical trials: Skin Toxicity
Breast Cancer
Eribulin in HER2 Negative Metastatic BrCa
Improvements in outcomes with metastatic breast cancer (MBC) have been observed in the last 30 years, however, overall prognosis remains poor with median survival of 2 to 3 years.
- Trial name
- NCT01827787
- Testing
- Eribulin
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- Dana-Farber Cancer Institute
Adverse Event, Cancer, Breast
Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial
The aim of this study is to determine whether the use of breast cancer patients' own electronic reporting of side effects to chemotherapy in a treatment setting has an impact on the handling of side effects and on the number of…
- Conditions
- Adverse Event, Cancer, Breast, Chemotherapeutic Toxicity, Patient Outcomes Assessments
- Trial name
- NCT02996201
- Testing
- Completion of PRO-CTCAE items before consultation
- Volunteers
- 700 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Melanoma
Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor
This clinical trial tests the feasibility of patient reported outcomes monitoring with early, rapid immunotherapy toxicity subspecialty care to improve side effect management for patients with melanoma receiving an immune…
- Trial name
- NCT07660666
- Testing
- Electronic Health Record Review, Internet-Based Intervention, Patient Navigation
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Pemphigus, Bullous Pemphigoid
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Pemphigus is a rare autoimmune life-threatening blistering condition affecting skin and mucous membranes. Pemphigus belongs to a family of polygenic disorders.
- Conditions
- Pemphigus, Bullous Pemphigoid, Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Trial name
- NCT05284929
- Testing
- A single blood sample for HLA typing
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sechenov University
Breast Neoplasms, Hypothyroidism
A Prospective Study of Hypothyroidism After Radiotherapy for Breast Cancer
This study is to prospectively investigate the incidence of hypothyroidism after postoperative radiotherapy and identify risk factors for development of hypothyroidism.
- Conditions
- Breast Neoplasms, Hypothyroidism, Radiation Toxicity
- Trial name
- NCT04528225
- Where
- China
- Volunteers
- 729 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Acneiform Eruption Due to Chemical, Xerosis Cutis
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
The goal of this clinical trial is to learn about HT-001 Topical Gel for treatment of EGFR inhibitor-induced skin toxicities. The main questions it aims to answer are: Determine the therapeutic effect of HT-001 for treatment of…
- Conditions
- Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
- Trial name
- CLEER (NCT05639933)
- Testing
- HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 152 people
- Sponsor
- Hoth Therapeutics, Inc.
Breast Neoplasms, Cardiovascular Diseases
Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer
In Europe, breast cancer is by far the most common form of cancer diagnosed in women today, accounting for 29% of all cases. The 5-year survival rate is approximately 90%.
- Trial name
- NCT02541435
- Where
- 2 sites in Norway
- Volunteers
- 1,600 people
- Sponsor
- St. Olavs Hospital
Breast Cancer
Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT
This research study is being done to carefully evaluate the effect of giving radiation therapy after temporary breast reconstruction.
- Trial name
- NCT01664091
- Testing
- post-mastectomy radiation therapy (PMRT), tissue expander (TE), acellular dermal matrix (ADM)
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Chemotherapeutic Toxicity
The Effects of a Nurse-led MHealth Program for Symptom Self-management of Breast Cancer Patients Undergoing Chemotherapy
Breast cancer (BC) survivors will experience multiple symptoms following chemotherapy. During the pandemic of COVID-19, the closure of clinics and fear of infection lead to BC patients' challenges in self-managing their multiple…
- Trial name
- mChemo (NCT05192525)
- Testing
- mChemotherapy
- Where
- China
- Volunteers
- 76 people
- Sponsor
- The Hong Kong Polytechnic University
Head and Neck Neoplasms
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to demonstrate the activity (response rate and rate of stable disease) of Iressa administered as a single agent escalated to a dose that produces grade 2 skin toxicity in patients with recurrent…
- Trial name
- NCT00519077
- Testing
- Gefitinib
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of Chicago
Vasculitis, Wegener's Granulomatosis
Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
This study will compare the safety and effectiveness of two drugs-methotrexate and mycophenolate mofetil (MPM)-in preventing disease recurrence in patients with Wegener's granulomatosis and related inflammatory blood vessel…
- Trial name
- NCT00004567
- Testing
- Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Breast Cancer
Managing Breast Cancer Treatment: Dyad's Perspectives on Treatment Decision, Financial and Family Burden.
The purpose of this study is to understand the financial burden and treatment decisions, based on both of patient's and family's perspectives in breast cancer patients who receive systemic chemotherapy, targeted therapy or…
- Trial name
- NCT05917444
- Where
- Taiwan
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Breast Cancer, Radiodermatitis
Photobiomodulation for Breast Cancer Radiodermatitis
A prospective single blind controlled randomized trial to evaluate the superiority of photobiomodulation (PBM) using LED-therapy in reducing the prevalence of radiodermatitis in breast cancer compared to usual local care.
- Conditions
- Breast Cancer, Radiodermatitis, Radiotherapy Side Effect, Radiation Dermatitis
- Trial name
- NCT04059809
- Testing
- Photobiomodulation
- Where
- Brazil
- Volunteers
- 48 people
- Sponsor
- AC Camargo Cancer Center
Breast Cancer
APBI: 27Gy in 5 Fractions for Early Breast Cancer
This study will test the safety of partial breast RT using 27Gy in 5 daily fractions which is expected to be equally tolerated as standard whole breast irradiation (WBI) based on radiobiologic modeling of the fibrosis response of…
- Trial name
- ACCEL (NCT02681107)
- Testing
- APBI 27Gy in 5 fractions
- Where
- Canada
- Volunteers
- 274 people
- Sponsor
- AHS Cancer Control Alberta
Cardiac Toxicity, Early-stage Breast Cancer
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
- Trial name
- NCT05559164
- Testing
- Lipitor 40mg Tablet
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer, Chemotherapeutic Toxicity
Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients
investigating the potential effect of Coenzyme Q10 in ameliorating and preventing the development of paclitaxel chemotherapeutic toxicity in breast cancer patients
- Trial name
- NCT06570811
- Testing
- Coenzyme Q10 200mg twice daily
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Damanhour University
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria.
- Trial name
- NCT01696500
- Testing
- Intravenous immunoglobulin
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Gastrointestinal Cancer, Head and Neck Cancer
Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy
The primary aim of this study is to investigate potential differences in vascular function between patients receiving 5-Fluorouracil (5-FU) chemotherapy, patients receiving chemotherapies other than 5-FU, cancer survivors who…
- Conditions
- Gastrointestinal Cancer, Head and Neck Cancer, Breast Cancer, Chemotherapy Effect
- Trial name
- NCT04042298
- Testing
- Arterial blood pressure, Skin microcirculatory blood flow, Brachial artery blood flow
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Kansas State University
Breast Cancer
The HeartSpare Plus 1B Trial
This study aims to compare the resource impact, acute toxicity and feasibility of different pan-lymph node radiotherapy techniques.
- Trial name
- NCT02771353
- Testing
- WT_vDIBH, VMAT_FB
- Volunteers
- 39 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Colorectal Carcinoma
SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment
Skin toxicity treatment in patients with advanced or metastatic colorectal cancer (mCRC) and non-mutated (wild-type) KRAS treated with panitumumab monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and…
- Trial name
- NCT01418742
- Testing
- Panitumumab
- Where
- 12 sites in Germany
- Volunteers
- 11 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH